• 1
    Felson D. Epidemiology of osteoarthritis. In: Brandt KD, Doherty M, Lohmander SL, editors. Osteoarthritis. 2nd ed. Oxford (UK): Oxford University Press; 2003. p. 916.
  • 2
    Guccione AA, Felson DT, Anderson JJ. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994; 84: 3518.
  • 3
    Yelin E. The economics of osteoarthritis. In: Brandt KD, Doherty M, Lohmander SL, editors. Osteoarthritis. 2nd ed. Oxford (UK): Oxford University Press; 2003. p. 1721.
  • 4
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Draft guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). Accessed December 29, 2003. URL:
  • 5
    Mazzuca, SA, Brandt KD, Katz BP. Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis? Osteoarthritis Cartilage 1997; 5: 21726.
  • 6
    Dieppe PA, Cushnaghan J, Shepstone L. The Bristol ‘OA500’ study: progression of osteoarthritis over 3 years and the relationship between clinical and radiographic changes at the knee joint. Osteoarthritis Cartilage 1997; 5: 8797.
  • 7
    Lethbridge-Çejku M, Hochberg MC, Scott WW Jr, Plato CC, Tobin JD. Longitudinal change in joint space of the knee: data from the Baltimore Longitudinal Study of Aging [abstract]. Arthritis Rheum 1995; 38 Suppl 9: S626.
  • 8
    Neuhauser KB, Anderson JJ, Felson DT. Rate of joint space narrowing in normal knees and knees with osteoarthritis [abstract]. Arthritis Rheum 1994; 37(9 Suppl ): S423.
  • 9
    Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. Which is the best radiographic protocol for a clinical trial of a structure-modifying drug in patients with knee osteoarthritis? J Rheumatol 2002; 29: 130820.
  • 10
    Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 2516.
  • 11
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double blind study. Arch Intern Med 2002; 162: 211323.
  • 12
    Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial: evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001; 44: 253947.
  • 13
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 103949.
  • 14
    Kellgren, JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis 1956; 16: 494502.
  • 15
    Ahlback S. Osteoarthritis of the knee: a radiographic investigation. Acta Radiol 1968; 277 Suppl: 772.
  • 16
    National Health and Nutrition Examination Survey II. Vital and Health Statistics arthropometric reference data and prevalence of overweight. DHHS Publication #PHS 87-1688. October 1987. p. 2122.
  • 17
    Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987; 8: 1239.
  • 18
    Lang JM. The use of a run-in to enhance compliance. Stat Med 1990; 9: 8795.
  • 19
    Archer GL, Polk RE. Treatment and prophylaxis of bacterial infections. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, editors. Harrison's principals of internal medicine. 14th ed. New York: McGraw-Hill; 1998. p. 85669.
  • 20
    Buckland-Wright C. Protocols for precise radio-anatomical positioning of the tibiofemoral and patellofemoral compartments of the knee. Osteoarthritis Cartilage 1995; 3(Suppl A): 7180.
  • 21
    Buckland-Wright JC, Macfarlane DG, Williams SA, Ward RJ. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis 1995; 54: 87280.
  • 22
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 23
    Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute; 1994.
  • 24
    Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts and microelectronic monitoring. J Clin Oncology 1993; 11: 118997.
  • 25
    Matsuyama JR, Mason BJ, Jue SG. Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill count. Ann Pharmacother 1993; 27: 8515.
  • 26
    Feinberg J. Effect of the arthritis health professional on compliance with use of resting hand splints by patients with rheumatoid arthritis. Arthritis Care Res 1992; 5: 1723.
  • 27
    Spector TD, Conaghan P, Buckland-Wright JC, Cline GC, Beary JF, Meyer JM. Risedronate produces disease modification and symptomatic benefit in treatment of knee osteoarthritis: results from the BRISK study [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S650.